In its Q1 16 trading update, UCB reported a robust revenue growth of 9% yoy at CER (11% reported) to €991m (higher than the consensus estimate), driven by the strong performance of the CVN trio (Cimzia, Vimpat and Neupro), offset to some extent by Keppra. The company does not report profitability numbers in the quarterly results. Management reiterated its FY 16 guidance: revenue of €4-4.1bn, recurring EBITDA of €970-1,010m and core EPS of €2.9-3.2.
06 May 2016
Strong start to the year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong start to the year
UCB S.A. (UCB:WBO) | 0 0 1.1% | Mkt Cap: 13,141m
- Published:
06 May 2016 -
Author:
Jyoti Prakash -
Pages:
2
In its Q1 16 trading update, UCB reported a robust revenue growth of 9% yoy at CER (11% reported) to €991m (higher than the consensus estimate), driven by the strong performance of the CVN trio (Cimzia, Vimpat and Neupro), offset to some extent by Keppra. The company does not report profitability numbers in the quarterly results. Management reiterated its FY 16 guidance: revenue of €4-4.1bn, recurring EBITDA of €970-1,010m and core EPS of €2.9-3.2.